Receptagen to Develop 'Growth Blocker' Monoclonal Antibody

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

SEATTLE--Receptagen Ltd. has begun formal clinical development of its first "growth blocker" drug, based on promising laboratory studies. The agent, a monoclonal antibody that blocks the B12 carrier protein trans-cobalamin II, triggered apoptosis in cancer cells by depleting vitamin B12, an essential enzyme co-factor for cell proliferation, said Receptagen president A. Charles Morgan Jr., PhD.

SEATTLE--Receptagen Ltd. has begun formal clinical developmentof its first "growth blocker" drug, based on promisinglaboratory studies. The agent, a monoclonal antibody that blocksthe B12 carrier protein trans-cobalamin II, triggered apoptosisin cancer cells by depleting vitamin B12, an essential enzymeco-factor for cell proliferation, said Receptagen president A.Charles Morgan Jr., PhD.

Articles in this issue
First Results of Avicidin Trials
Chemo Patients Often Develop Menstrual Irregularities
Growth Factor Receptor Blockade Moving From Laboratory to Clinic
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigation
Vinorelbine Plus Chemo Promising in Advanced Disease
Bone Substudy a Part of Tamoxifen Prevention Trial
Ultrasound Breast Screens Useful in Selected Women
New Roles Forecast for Endocrine Therapy
Antisense Drug Against BCL-2 Effective in Animal Cancer Models
Anticancer Drugs From Zeneca in Regulatory Phase of Development
Osteosarcoma Chemo Regimens Debated
Primary Chemotherapy Allows Breast-Conserving Surgery in French Study
Cancer Care, Inc. Sponsors Make-Up Clinics for Chemo Patients
$2 Billion Budget for NCI Proposed
Risk of Gyn Cancer Increases After Diagnosis of Breast Cancer
Recent Videos
3 experts in this video
Related Content
Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC

ONCOLOGY Staff
January 17th 2025
Article

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

NSCLC Experts Ponder Best First-Line Treatment Options

NSCLC Experts Ponder Best First-Line Treatment Options

ONCOLOGY Staff
January 17th 2025
Article

The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD
January 6th 2025
Podcast

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Mayo Clinic on AE Management Strategies for EGFR-Mutated NSCLC

Mayo Clinic on AE Management Strategies for EGFR-Mutated NSCLC

ONCOLOGY Staff
January 17th 2025
Article

The combination of amivantamab plus lazertinib has emerged as a potential treatment option for patients with EGFR-mutated NSCLC and has shown sufficient efficacy responses.

Shwetal Mehta, PhD, highlights early phase clinical trials, biomarker testing strategies, and potential next steps for research in the brain cancer field.

Leading Scientifically Rigorous Research in Novel Brain Cancer Therapies

Russ Conroy
January 17th 2025
Article

Shwetal Mehta, PhD, highlights early phase clinical trials, biomarker testing strategies, and potential next steps for research in the brain cancer field.